Vivos Therapeutics price target lowered to 75c from $1.75 at Alliance Global

Alliance Global lowered the firm's price target on Vivos Therapeutics to 75c from $1.75 and keeps a Neutral rating on the shares after the company reported Q1 earnings on May 20. The balance sheet needs "significant reinforcement," which creates elevated financial risk, says the analyst, who is lowering the firm's price target based on increased expected equity dilution.